НовостиBenzingaReported Saturday, FDA Accepts Genentech’s Vamikibart BLA For Uveitic Macular Edema With Approval Decision Expected By July 2027, Following Phase III Data Showing Sustained Improvements At 52 Weeks Reported Saturday, FDA Accepts Genentech’s Vamikibart BLA For Uveitic Macular Edema With Approval Decision Expected By July 2027, Following Phase III Data Showing Sustained Improvements At 52 Weeks Benzinga 2026.10.12 08:05 (GMT+0) Открыть на Benzinga Другие новости
